As leaders of a biosimilar company launched on the promise and value of biosimilars after the Affordable Care Act and a Louisiana community oncology practice working hard to utilize biosimilars, we believe biosimilars should be celebrated, rewarded, and boosted through new policy changes this year.  In 2019, former FDA commissioner Dr. Scott Gottlieb argued that we should not give up on biosimilars and prematurely regulate prices as suggested by Bach/Trusheim.  READ MORE